Table 1

Clinical characteristics of 609 adults with recurring ALL

CharacteristicNo. patients
Age at first diagnosis  
    15-19 y 117 
    20-34 y 236 
    35-49 y 49 
    Older than 50 y 74 
Sex  
    Male 382 
    Female 227 
WBC count at first diagnosis  
    Less than 10 × 109/L 248 
    10–49 × 109/L 178 
    More than 50 × 109/L 181 
    Unknown 
Immunophenotype (44 unknown)  
    B precursor 409 
    T-cell 92 
    Mature B 12 
    Null 30 
    Mixed 22 
    Unknown 44 
Ph status (56 unknown)  
    Positive 120 
    Negative 433 
Risk group at first diagnosis (67 unknown)  
    Standard 287 
    High 135 
    Very high 120 
    Unknown 67 
Initial treatment at first diagnosis*  
    CR1  
        Chemotherapy 440 
        Sibling allograft 60 
        MUD 17 
        Autograft 80 
        Other 5 
    Preremission  
        Sibling allograft 
        Autograft 
Time from diagnosis to relapse  
    Less than 1 y 333 
    1-2 y 160 
    More than 2 y 116 
Site of relapse, no. patients (8 unknown)  
    BM alone 523 
    BM + CNS 33 
    CNS alone 22 
    Extramedullary 23 
    Unknown 
CharacteristicNo. patients
Age at first diagnosis  
    15-19 y 117 
    20-34 y 236 
    35-49 y 49 
    Older than 50 y 74 
Sex  
    Male 382 
    Female 227 
WBC count at first diagnosis  
    Less than 10 × 109/L 248 
    10–49 × 109/L 178 
    More than 50 × 109/L 181 
    Unknown 
Immunophenotype (44 unknown)  
    B precursor 409 
    T-cell 92 
    Mature B 12 
    Null 30 
    Mixed 22 
    Unknown 44 
Ph status (56 unknown)  
    Positive 120 
    Negative 433 
Risk group at first diagnosis (67 unknown)  
    Standard 287 
    High 135 
    Very high 120 
    Unknown 67 
Initial treatment at first diagnosis*  
    CR1  
        Chemotherapy 440 
        Sibling allograft 60 
        MUD 17 
        Autograft 80 
        Other 5 
    Preremission  
        Sibling allograft 
        Autograft 
Time from diagnosis to relapse  
    Less than 1 y 333 
    1-2 y 160 
    More than 2 y 116 
Site of relapse, no. patients (8 unknown)  
    BM alone 523 
    BM + CNS 33 
    CNS alone 22 
    Extramedullary 23 
    Unknown 
*

One BMT on unknown date.

Other indicates one reduced-intensity sibling allogeneic HSCT, one reduced-intensity MUD allogeneic HSCT, one reduced-intensity haploidentical HSCT, one fully conditioned haploidentical HSCT, and one unknown type.

Preremission indicates HSCT performed in absence of achieving CR1.

Close Modal

or Create an Account

Close Modal
Close Modal